Family · Pharmaceutical analytical standards
Ruxolitinib
An inhibitor of the JAK1 and JAK2 kinases, which relay the signals of many growth factors and of inflammation: approved in the United States in 2011 for myelofibrosis, it is also used in polycythaemia vera and graft-versus-host disease. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?As a cream, in 2022 it became the first medicine approved in the United States to restore skin colour in vitiligo.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
